Prognostic versus predictive value of biomarkers in oncology

被引：265

作者：

Oldenhuis, C. N. A. M. ^{[1
]}

Oosting, S. F. ^{[1
]}

Gietema, J. A. ^{[1
]}

de Vries, E. G. E. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 RB Groningen, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2008年 / 44卷 / 07期

关键词：

prognostic factor; predictive factor; biomarker; therapy;

D O I：

10.1016/j.ejca.2008.03.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Numerous options are currently available for tumour typing. This has raised intense interest in the elucidation of prognostic and predictive markers. A prognostic biomarker provides information about the patients overall cancer outcome, regardless of therapy, whilst a predictive biomarker gives information about the effect of a therapeutic intervention. A predictive biomarker can be a target for therapy Amongst the genes that have proven to be of relevance are well-known markers such as ER, PR and HER2/neu in breast cancer, BCR-ABL fusion protein in chronic myeloid leukaemia, c-KIT mutations in GIST tumours and EGFR1 mutations in NSCLC. Several reasons for the difficult elucidation of new markers will be addressed including the involvement of cellular pathways in tumour biology instead of single genes and interference in disease outcome as a result of anticancer therapies. Future perspectives for the development of prognostic and predictive markers will be given. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：946 / 953

页数：8

共 77 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2]

AMADO RG, 2008, GASTR CANC S

[3] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[4] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[5] Linking oncogenic pathways with therapeutic opportunities [J].

Bild, Andrea H. ;

Potti, Anil ;

Nevins, Joseph R. .

NATURE REVIEWS CANCER, 2006, 6 (09) :735-U13

[6] Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding [J].

Bin, Lianghua ;

Thorburn, Jacqueline ;

Thomas, Lance R. ;

Clark, Peter E. ;

Humphreys, Robin ;

Thorburn, Andrew .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (38) :28189-28194

[7] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer [J].

Buyse, Marc ;

Loi, Sherene ;

van't Veer, Laura ;

Viale, Giuseppe ;

Delorenzi, Mauro ;

Glas, Annuska M. ;

d'Assignies, Mahasti Saghatchian ;

Bergh, Jonas ;

Lidereau, Rosette ;

Ellis, Paul ;

Harris, Adrian ;

Bogaerts, Jan ;

Therasse, Patrick ;

Floore, Arno ;

Amakrane, Mohamed ;

Piette, Fanny ;

Rutgers, Emiel ;

Sotiriou, Christos ;

Cardoso, Fatima ;

Piccart, Martine J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17) :1183-1192

[8] Targeting TRAIL agonistic receptors for cancer therapy [J].

Carlo-Stella, Carmelo ;

Lavazza, Cristiana ;

Locatelli, Alberta ;

Vigano, Lucia ;

Gianni, Alessandro M. ;

Gianni, Luca .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2313-2317

[9]

CLARK GM, 1991, CANCER RES, V51, P944

[10] KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours [J].

Debiec-Rychter, Maria ;

Sciot, Raf ;

Le Cesne, Axel ;

Schlemmer, Marcus ;

Hohenberger, Peter ;

van Oosterom, Allan T. ;

Blay, Jean-Yves ;

Leyvraz, Serge ;

Stul, Michel ;

Casali, Paolo G. ;

Zalcberg, John ;

Verweij, Jaap ;

Van Glabbeke, Martine ;

Hagemeijer, Anne ;

Judson, Ian .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1093-1103

← 1 2 3 4 5 6 7 8 →